TORNALATE
LOE ApproachingNDAINHALATIONAEROSOL, METERED
Approved
Dec 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TORNALATE is a metered-dose aerosol inhaled small molecule approved in 1984 for respiratory indications. The specific mechanism of action and indications are not publicly detailed in available data. It is marketed by Sanofi as a mature respiratory therapeutic.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100); commercial teams likely in transition or optimization mode rather than growth phase.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TORNALATE offers limited growth opportunities due to its approaching LOE and zero linked job openings. Career roles are concentrated in defending market share and managing payer relationships rather than innovation or expansion. This is a consolidation-and-harvest assignment, suitable for professionals managing decline or executing efficiency strategies.
Brand ManagerField Sales Representative
Worked on TORNALATE at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.